Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple ...

The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for the use of GSK’s Blenrep (belantamab ...

GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval ...

GSK (NYSE:GSK) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed ...

Who doesn’t love a comeback story? Certainly not GSK, which has found a way to resuscitate its cancer treatment Blenrep as a ...

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

GSK (LSE:GSK) recently received FDA approval for Nucala for COPD treatment, potentially enhancing its market presence.

GSK plc’s Blenrep (belantamab mafodotin) is heading back to the market three years after being withdrawn, with the EMA’s ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended six novel medicines for approval at its ...

GSK plc has received approval for Blenrep combinations from Japan's Ministry of Health, Labour and Welfare (MHLW) for the ...

(RTTNews) - British drug maker GSK plc (GSK.L, GSK) announced Monday the approval of Blenrep combinations by Japan's Ministry of Health, Labour and Welfare or MHLW for the treatment of adults with ...